Long-term survival among men with conservatively treated localized prostate cancer.
about
Considerations for observational research using large data sets in radiation oncologyScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsProspective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer.Improving appropriate selection of radical prostatectomy for prostate cancer.Therapeutic value of quinazoline-based compounds in prostate cancer.Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patientsFifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerThe Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.Prostate cancer: 2. Natural history.Screening for prostate cancer: estimating the magnitude of overdetection.Prostate cancer screening: waiting for Godot.The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer ModelThe economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer ModelComorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease.Challenges in prognostic analysis.Observation in the management of localized prostate cancer.Radical prostatectomy as treatment for prostate cancerCancer survivorship and aging : moving the science forward.On the role of intensity-modulated radiation therapy in radiation oncology.A molecular correlate to the Gleason grading system for prostate adenocarcinoma.Managed care market share and primary treatment for cancerProstate-specific antigen-based screening: controversy and guidelinesManagement of high-risk localized prostate cancer.Prostate cancer management: (1) an update on localised diseaseThe association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study.The role of alpha-blockers in the management of prostate cancerReduced mortality: the unexpected impact of a telephone-based care management intervention for older adults in managed careQuality of preventive care before and after prostate cancer diagnosis.Expectant management: an option for localized prostate cancer.Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results.Watchful waiting for prostate cancer: a review article.Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.Selecting candidates for radical prostatectomy.Long-term outcome among men with conservatively treated localised prostate cancer.Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Survival following primary androgen deprivation therapy among men with localized prostate cancer
P2860
Q24289442-D60462D4-DCB5-48A8-8130-A3579C462E72Q24608493-4E7EAF92-ECE4-4739-ACD0-6B32EA4418D7Q33561172-4AE6F415-3FE8-4D22-8671-D8BD41AA78F2Q33610863-6B8754FD-844C-4A65-8220-6719488D54F0Q33648487-64E5621C-A139-4407-8DBB-78E5154EDDCFQ33746225-70A34608-D101-4320-826F-225BCBD2801DQ33773297-DE3A2261-BFF6-4A4E-96EC-3B0B077F3AEFQ33877542-94D213A9-4297-44B4-B9DB-083A6EE45708Q33958709-EB80F511-536D-4DBE-A5E4-9451F2DA735DQ34029755-EA1108B3-5895-417F-B8C5-0D173FE3D5E4Q34030152-2A9D746F-DD64-4D25-8528-687824B33C55Q34030164-2EFB613B-FF7E-4A00-B394-A9110412A34FQ34037487-081E3C41-A4C5-4FDC-ACED-3A739C0C90E5Q34037498-AF311077-D3EB-4189-A676-DD479AF0570CQ34051264-AB3FED55-7C5F-4A91-B2A1-8E03CC646DE3Q34223368-1FA0A2DB-34DF-465A-9D1E-083ADB5326ABQ34234521-E16BA87B-2C27-47F3-96C0-109F84A53895Q34432107-4E27EACD-596F-489E-8641-822D65ED52E3Q34700696-B2CF5D05-5F26-4B82-A67D-1AE56409CC9BQ34767150-794FCAB8-4438-4668-815D-AFA87ED6ADD4Q34984241-77BB6F61-2DA5-4467-9F0B-95CA395A6D4AQ35193573-9DBF10D5-B0A0-464F-9460-32303081B946Q35211931-7B9DF747-74F6-4435-909F-3A3B878E31ABQ35503645-CDD69FA0-B7AB-4F06-8326-9F201D00DB63Q35517935-EDF472D1-B0F9-44FC-B445-753F9719AE36Q35596262-161586D2-9DE9-4E8E-BE1B-459D017FCC60Q35784033-9E71C1CC-A2EF-4B2C-9736-D28F9A7EF05EQ35955061-83364B76-ABFD-4A29-9AA4-E80A6A74734BQ36104439-B47620C0-8B17-4D12-ADAD-53076C6ABCA5Q36244110-FB842984-A56D-4014-9D3C-738DE5CAADB6Q36326194-757DBFE8-37CB-4370-954D-EB3989C9395AQ36364398-59053432-DE5B-480E-AAAD-3B83B1199EF4Q36520484-86DC3FF4-C5B4-42BF-BFD4-37FC872DF0C8Q36582865-7A1413A9-6979-4C76-8F53-38A461E4FCB7Q36598371-D84AC565-6B68-400B-B33B-17242573FF1EQ36611890-C8CC3757-A8BF-4C58-9635-AC04DB1BB522Q36765569-AF4A8E33-2936-4D9B-A9CB-C59EDC5B6FFBQ36866123-9B1C65D6-4AAA-46A6-B6B2-B8AC7EC6263EQ37037804-54FEA869-6151-4CEE-86B6-208ACB59FA97Q37104386-B4A5C88D-F74D-46D6-8910-B31E28E9EE69
P2860
Long-term survival among men with conservatively treated localized prostate cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Long-term survival among men with conservatively treated localized prostate cancer.
@en
Long-term survival among men with conservatively treated localized prostate cancer.
@nl
type
label
Long-term survival among men with conservatively treated localized prostate cancer.
@en
Long-term survival among men with conservatively treated localized prostate cancer.
@nl
prefLabel
Long-term survival among men with conservatively treated localized prostate cancer.
@en
Long-term survival among men with conservatively treated localized prostate cancer.
@nl
P2093
P1476
Long-term survival among men with conservatively treated localized prostate cancer.
@en
P2093
B E Storer
D G Fryback
P C Albertsen
P304
P356
10.1001/JAMA.1995.03530080042039
P407
P577
1995-08-01T00:00:00Z